Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by respimat® soft mist™ inhaler: Results of phase ii single-dose crossover studies

Respiration

Volumn 71, Issue 5, 2004, Pages 469-476

  Koehler, D ^a   Pavia, D ^a,b   Dewberry, H ^b   Hodder, R ^c  

^a KRANKENHAUS KLOSTER GRAFSCHAFT   (Germany)

^b BOEHRINGER INGELHEIM LTD   (United Kingdom)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Asthma; COPD; Paradoxical bronchoconstriction; Preservatives; Respimat ; Soft Mist Inhaler

Indexed keywords

BENZALKONIUM CHLORIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; EDETIC ACID;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; INHALER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; ASTHMA; BENZALKONIUM COMPOUNDS; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; CHLOROFLUOROCARBONS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS, PHASE II; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EDETIC ACID; EQUIPMENT DESIGN; FEMALE; HUMANS; INCIDENCE; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 5644244791     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080631     Document Type: Article

References (44)

1. Hochrainer D, Hoelz H: Comparison of cloud velocities delivered from Respimat® soft mist inhaler or MDIs. J Aerosol Med 2001;14(suppl 3):386.
2. Zierenberg B, Eicher J, Dunne S, Freund B: Boehringer Ingelheim nebulizer BINEB: A new approach to inhalation therapy; in Dalby RN, Byron PR, Farr SJ (eds): Respiratory Drug Delivery V. Buffalo Grove, Interpharm Press, 1996, pp 187-193.
3. Newman SP, Steed KP, Reader SJ, Hooper G, Zierenberg B: Efficient delivery to the lungs of flunisolide aerosol from a new portable handheld multidose nebulizer. J Pharm Sci 1996:85:960-964.
4. Newman SP, Steed KP, Towse L, Zierenberg B: The BINEB® (final prototype): A novel handheld multidose nebuliser evaluated by gamma scintigraphy. Eur Respir J 1996;9(suppl 23):S441-S442.
5. Steed KP, Towse LJ, Freund B, Newman SP: Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from prototype III hand-held multidose Respimat® nebuliser. Eur J Pharm Sci 1997;5:55-61.
6. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H: Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat® with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957-963.
7. Pavia D, Moonen D: Preliminary data from phase II studies with Respimat®, a propellantfree soft mist inhaler. J Aerosol Med 1999;12(suppl 1):S33-S39.
8. Smith SJ, Bernstein JA: Therapeutic use of lung aerosols; in Lenfant C (ed): Lung Biology in Health and Disease: Inhalation Aerosols. New York, Dekker, 1996, vol 94, pp 233-269.
9. Pavia D: Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology 1997;2(suppl 1):S5-S10.
10. Crompton GK: Problems patients have using pressurized aerosol inhalers. Eur Respir Dis Suppl 1982;119:101-104.
11. Larsen JS, Hahn M, Ekholm B, Wick KA: Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma 1994;31:193-199.
12. Erickson S, Horton A, Kirking D: Assessing metered dose inhaler technique: Comparison of observation versus patient self-report. J Asthma 1998;35:575-583.
13. Van Beerendonk I, Mesters I, Mudde A, Tan TD: Assessment of the inhalation technique in out-patients with asthma or chronic obstructive pulmonary disease using a metered dose inhaler or dry powder device. J Asthma 1998;35:273-279.
14. Kamps A, Brand P, Roorda R: Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. Acta Paediatr 2002;91:159-163.
15. Hirst P, Pitcairn G, Richards J, Rohatagi S, Gillen M, Newman SP: Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. J Aerosol Med 2001;14:155-165.
16. Berg E, Madsen J, Bisgaard H: In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J 1998;12:472-476.
17. Partridge MR: Metered-dose inhalers and CFCs: What respiratory physicians need to know. Respir Med 1994;88:645-647.
18. Burnell P, Small T, Doig S, Johal B, Jenkins R, Gibson G: Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med 2001;95:324-330.
19. Everard M, Devadason S, Souef P: Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997;91:624-628.
20. Nicklas RA: Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990;85:959-964.
21. Miszkiel KA, Beasley R, Rafferty P, Holgate ST: The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 1988;25:157-163.
22. Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salone CM, Woolcock AJ: Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride. Am Rev Respir Dis 1990;141:1405-1408.
23. Beasley R, Fishwick D, Miles JF, Hendeles L: Preservatives in nebulizer solutions: Risks without benefit. Pharmacotherapy 1998;18:130-139.
24. Maesen FPV, Van Noord JA, Smeets JJ, Greefhorst APM, Dewberry H, Cornelissen PJG: Dose-range finding study comparing a new soft mist inhaler with a conventional metered dose inhaler (MDI) to deliver fenoterol in patients with asthma (abstract). Eur Respir J 1997:10(suppl 25):128S.
25. Goldberg J, Freund E, Jahnel B, Hinzmann R, on behalf of the Berodual Respimat® study team. Combination fenoterol/ipratropium bromide delivered via a new soft mist inhaler: Dose-range finding study in patients with asthma, in comparison with a conventional metered dose inhaler (MDI) (abstract). Am J Respir Crit Care Med 1998;157:A401.
26. Data on file; Boehringer Ingelheim: Study U97-3212. 1997.
27. Littner M, Taylor JR, Ghafouri M, Witek TJ, Sepulveda CA, Tacoma WA, Ridgefield CT: A dose-ranging study of ipratropium bromide solution delivered via a novel soft mist inhaler in patients with chronic obstructive pulmonary disease (COPD) (abstract). Eur Respir J 2000;16(suppl 31):55S.
28. Data on file; Boehringer Ingelheim: Study U97-3214. 1997.
29. Vincken W, Aumann J, Radermecker M, Slabbynck H, Stappaerts I, Demedts M, Moonen D: Comparison of pharmacodynamics, efficacy and safety of fenoterol inhaled from a novel pocket-sized inhaler and from a metered-dose inhaler (MDI) (abstract). Eur Respir J 1997:10(suppl 25):239S.
30. Kunkel G, Magnussen H, Bergmann KC, Juergens UR, de Mey C, Freund E, Hinzmann R, Beckers B: Respimat® (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000;67:306-314.
31. Data on file; Boehringer Ingelheim: Study U97-0123. 1997.
32. Iacono P, Velicitat P, Guemas E, Leclerc V, Thébault J-J: Improved delivery of ipratropium bromide using Respimat® (a new soft mist inhaler) compared with a conventional metered dose inhaler: Cumulative dose response study in patients with COPD. Respir Med 2000;94:490-495.
33. Hodder RV, Pavia D, Dewberry H, Alexander KM, Iacono P, Ponitz HH, Beck E: Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide alone or combined with fenoterol hydrobromide inhaled from a new soft mist inhaler and from a conventional metered dose inhaler in asthma and COPD patients. Eur Respir J 2002;20:246S.
34. Beasley CR, Rafferty P, Holgate ST: Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. BMJ 1987;9:1197-1198.
35. Asmus MJ, Barros MD, Liang J, Chesrowan SE, Hendeles L: Pulmonary function response to EDTA, an additive in nebulised bronchodilators. J Allergy Clin Immunol 2001;107:68-72.
36. Yarbrough J, Mansfield LE, Ting S: Metered dose inhaler-induced bronchospasm in asthmatic patients. Ann Allergy 1985;55:25-27.
37. Kwong T, Flatt A, Crane J, Beasley R: The effect of benzalkonium chloride on the bronchodilator response to salbutamol nebuliser solution. NZ Med J 1990;103:457.
38. Rafferty P, Beasley R, Holgate ST: Comparison and the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution. Thorax 1988;43:446-450.
39. Henry RL, Hankin RG, Abramson R: Comparison of preservative-free and preservative-containing ipratropium bromide. Aust Paediatr J 1989;25:86-88.
40. Orehek J Charpin D, Velardocchio JM, Grimaud C: Bronchomotor effect of bronchoconstriction-induced deep inspirations in asthmatics. Am Rev Respir Dis 1980;121:297-305.
41. Orehek J, Nicoli MM, Delpierre S, Beaupre A: Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. Am Rev Respir Dis 1981;123:269-272.
42. Charpin D, Beaupre A, Orehek J: Deep-inspiration induced bronchoconstriction: A mechanism for beclomethasone aerosol intolerance. Eur J Respir Dis 1983;64:494-497.
43. Fryer A, Maclagan J: Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur J Pharmacol 1987;139:187-191.
44. Cocchetto DM, Sykes RS, Spector S: Paradoxical bronchoconstriction after use of inhalation aerosols: A review of the literature. J Asthma 1991;28:49-53.